PharmExec Picks:
Having trouble viewing this e-mail? Click here.
feed back

Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE


Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what's trending on social media.

Top 5 Stories :
Pulling Back the Curtains on Obamacare Rx Usage
The 2015 Obamacare Exchange Rx insurance offerings will be presented to patients on November 15th. At this point, what insights do American Rx brand managers and marketers actually have on the results of the Obamacare Rx experience in 2014?
Read more
EMA Clinical Data Disclosure Plan Under Fire
The EMA might have expected that the publication of its plan for proactive release of clinical reports would receive a warm welcome. But, Reflector writes, it is far from a roaring success.
Read more
The Pharma Leadership Challenge: Thawing the “Frozen” Middle Managers
The challenge for senior leadership is to enable layers of middle management to work to their full potential. ‘Failing fast’ should become the new mantra if pharma is going to drive greater innovation and creativity.
Read more
The Human Microbiome — Our Body's Secret Weapon
Sparked in part by the Human Microbiome Project, a collective group of scientists and researchers are just beginning to unlock the full power of the human microbiome, the collective genomes of all microorganisms present in or on the human body.
Read more
Dealmaking: Staying Ahead of the Curve
Amid the continued surge in M&A activity, Michael Swanick asks, what are the crucial considerations pharma executives should weigh before sitting down at the deals table?
Read more
Trending on Social Media :
How Do You Solve a Problem like England's Cancer Drugs Fund?
The Cancer Drugs Fund  started out with positive headlines, but over time it’s fallen out of favour with policy makers.
Read more
Is Pfizer Ready for Another Acquisition?
This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt.
Read more
New Patent-Defense Path for Pharma
Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
Read more
Follow Us